Horizon Discovery Group PLC (HZD) Earns Speculative Buy Rating from Beaufort Securities
Horizon Discovery Group PLC (LON:HZD)‘s stock had its “speculative buy” rating reiterated by Beaufort Securities in a research report issued on Wednesday.
Several other analysts have also recently commented on HZD. Panmure Gordon restated a “buy” rating and set a GBX 270 ($3.52) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, June 1st. Numis Securities Ltd restated a “buy” rating and set a GBX 252 ($3.29) price target on shares of Horizon Discovery Group PLC in a report on Wednesday, June 1st. Finally, N+1 Singer restated a “buy” rating and set a GBX 194 ($2.53) price target on shares of Horizon Discovery Group PLC in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Horizon Discovery Group PLC currently has an average rating of “Buy” and a consensus target price of GBX 217.25 ($2.84).
Horizon Discovery Group PLC (LON:HZD) traded up 0.64% during midday trading on Wednesday, reaching GBX 157.00. 100,979 shares of the company were exchanged. Horizon Discovery Group PLC has a one year low of GBX 125.00 and a one year high of GBX 188.06. The firm’s 50-day moving average is GBX 160.22 and its 200-day moving average is GBX 160.62. The firm’s market cap is GBX 147.72 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/horizon-discovery-group-plc-hzd-earns-speculative-buy-rating-from-beaufort-securities.html
About Horizon Discovery Group PLC
Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.